Tranexamic acid and aprotinin reduce postoperative bleeding and transfusions during primary coronary revascularization

Anesthesia and Analgesia

Volumn 87, Issue 2, 1998, Pages 258-265

  Mongan, Paul D ^a   Brown, Robert S ^b   Thwaites, Brian K ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; PLACEBO; TRANEXAMIC ACID;

ADULT; AGED; ARTICLE; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THORAX DRAINAGE;

ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CHEST TUBES; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; DRAINAGE; FEMALE; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; TRANEXAMIC ACID;

EID: 0031852748     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199808000-00005     Document Type: Article

References (33)

1. Harker LA, Malpass TW, Branson HE, et al. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980;56:824-34.
2. Cramer EM, Lu H, Caen JP, et al. Differential redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation [published erratum appears in Blood 1991;78:545]. Blood 1991; 77:694-9.
3. Despotis GJ, Santoro SA, Spitznagel E, et al. On-site prothrombin time, activated partial thromboplastin time, and platelet count: a comparison between whole blood and laboratory assays with coagulation factor analysis in patients presenting for cardiac surgery. Anesthesiology 1994;80:338-51.
4. Despotis GJ, Santoro SA, Spitznagel E, et al. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1994;107:271-9.
5. Lu H, Du Buit C, Soria J, et al. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy. Thromb Haemost 1994;72: 438-43.
6. Teufelsbauer H, Proidl S, Havel M, Vukovich T. Early activation of hemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis. Thromb Haemost 1992; 68:250-2.
7. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome - the International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg 1997;85:1258-67.
8. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vase Anesth 1992;6: 76-100.
9. Davis R, Whittington R. Aprotinin: a review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 1995;49:954-83.
10. Lemmer JH Jr, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens [see comments]. Ann Thorac Surg 1996;62: 1659-67.
11. Blauhut B, Harringer W, Bettelheim P, et al. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994;108:1083-91.
12. Huang H, Ding W, Su Z, Zhang W. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg 1993;106:11-8.
13. Shigeta O, Kojima H, Jikuya T, et al. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation 1997;96:569-74.
14. van Oeveren W, Harder MP, Roozendaal KJ, et al. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-96.
15. Dietrich W, Spath P, Ebell A, Richter JA. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg 1997;113:194-201.
16. Longstaff C. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coagul Fibrinolysis 1994;5:537-42.
17. Lu H, Soria C, Li H, et al. Role of active center and lysine binding sites of plasmin in plasmin-induced platelet activation and disaggregation. Thromb Haemost 1991;65:67-72.
18. Karski JM, Teasdale SJ, Norman P, et al. Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid: double-blind, randomized clinical trial. J Thorac Cardiovasc Surg 1995;110:835-42.
19. Rousou JA, Engelman RM, Flack JE III, et al. Tranexamic acid significantly reduces blood loss associated with coronary revascularization [see comments]. Ann Thorac Surg 1995;59:671-5.
20. Katsaros D, Petricevic M, Snow NJ, et al. Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients. Ann Thorac Surg 1996;61: 1131-5.
21. Brown RS, Thwaites BK, Mongan PD. Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: a double-blind, randomized, placebo controlled trial. Anesth Analg 1997;85:963-70.
22. Menichetti A, Tritapepe L, Ruvolo G, et al. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. J Cardiovasc Surg (Torino) 1996;37:401-7.
23. Speekenbrink RG, Vonk AB, Wildevuur CR, Eijsman L. Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Ann Thorac Surg 1995;59:438-42.
24. Hardy JF, Desroches J. Natural and synthetic antifibrinolytics in cardiac surgery [see comments]. Can J Anaesth 1992;39:353-65.
25. Unsworth-White MJ, Herriot A, Valencia O, et al. Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. Ann Thorac Surg 1995;59:664-7.
26. Price Stover E, Siegel LC, Parks R, et al. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines. Anesthesiology 1998;88:327-33.
27. Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993;105:147-52.
28. Kalangos A, Tayyareci G, Pretre R, et al. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg 1994;8:651-6.
29. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency: a multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994;107:543-51.
30. Havel M, Grabenwoger F, Schneider J, et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994;107:807-10.
31. Slaughter TF, Faghih F, Greenberg CS, et al. The effects of ∈-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. Anesth Analg 1997;85:1221-6.
32. Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery: a controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 1992;77:38-46.
33. Spiess BD, Tuman KJ, McCarthy RJ, et al. Thromboelastography as an indicator of post-cardiopulmonary bypass coagulopathies. J Clin Monit 1987;3:25-30.